-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Lowers Price Target to $24

Benzinga·07/11/2025 18:14:39
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and lowers the price target from $77 to $24.